{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T17:59:47Z","timestamp":1792691987049,"version":"4.5.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Mental Health Res"],"DOI":"10.1038\/s44184-025-00174-2","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T11:20:06Z","timestamp":1764156006000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["FDA-authorized software as a medical device in mental health: a perspective on evidence, device lineage, and regulatory challenges"],"prefix":"10.1038","volume":"4","author":[{"given":"Julian","family":"Herpertz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel D.","family":"Stern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nils","family":"Opel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Reininghaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Torous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,26]]},"reference":[{"key":"174_CR1","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s41746-021-00386-8","volume":"4","author":"A Wu","year":"2021","unstructured":"Wu, A. et al. Smartphone apps for depression and anxiety: a systematic review and meta-analysis of techniques to increase engagement. npj Digit Med. 4, 20 (2021).","journal-title":"npj Digit Med"},{"key":"174_CR2","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1002\/wps.21183","volume":"23","author":"J Linardon","year":"2024","unstructured":"Linardon, J. et al. Current evidence on the efficacy of mental health smartphone apps for symptoms of depression and anxiety. A meta-analysis of 176 randomized controlled trials. World Psychiatry 23, 139\u2013149 (2024).","journal-title":"World Psychiatry"},{"key":"174_CR3","doi-asserted-by":"publisher","first-page":"e1136","DOI":"10.1016\/S2468-2667(24)00249-4","volume":"9","author":"HF Sit","year":"2024","unstructured":"Sit, H. F. et al. Digital mental health: a potential opportunity to improve health equity in China. Lancet Public Health 9, e1136\u2013e1141 (2024).","journal-title":"Lancet Public Health"},{"key":"174_CR4","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1002\/cpt.3260","volume":"116","author":"L Masanneck","year":"2024","unstructured":"Masanneck, L. & Stern, A. D. Tracing digital therapeutics research across medical specialties: evidence from ClinicalTrials.gov. Clin. Pharma Therapeutics 116, 177\u2013185 (2024).","journal-title":"Clin. Pharma Therapeutics"},{"key":"174_CR5","doi-asserted-by":"publisher","first-page":"e857","DOI":"10.1016\/S2589-7500(24)00119-5","volume":"6","author":"S Sun","year":"2024","unstructured":"Sun, S., Simonsson, O., McGarvey, S., Torous, J. & Goldberg, S. B. Mobile phone interventions to improve health outcomes among patients with chronic diseases: an umbrella review and evidence synthesis from 34 meta-analyses. Lancet Digit Health 6, e857\u2013e870 (2024).","journal-title":"Lancet Digit Health"},{"key":"174_CR6","unstructured":"Cox D The Guardian. \u2018They thought they were doing good but it made people worse\u2019: why mental health apps are under scrutiny. https:\/\/www.theguardian.com\/society\/2024\/feb\/04\/they-thought-they-were-doing-good-but-it-made-people-worse-why-mental-health-apps-are-under-scrutiny (2024)."},{"key":"174_CR7","doi-asserted-by":"publisher","DOI":"10.1093\/jlb\/lsac015","volume":"9","author":"DA Simon","year":"2022","unstructured":"Simon, D. A., Shachar, C. & Cohen, I. G. Skating the line between general wellness products and regulated devices: strategies and implications. J. Law Biosci. 9, lsac015 (2022).","journal-title":"J. Law Biosci."},{"key":"174_CR8","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1001\/jama.2022.0047","volume":"327","author":"DA Simon","year":"2022","unstructured":"Simon, D. A., Shachar, C. & Cohen, I. G. At-home diagnostics and diagnostic excellence: devices vs general wellness products. JAMA 327, 523 (2022).","journal-title":"JAMA"},{"key":"174_CR9","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41746-023-00777-z","volume":"6","author":"C Wang","year":"2023","unstructured":"Wang, C., Lee, C. & Shin, H. Digital therapeutics from bench to bedside. npj Digit Med. 6, 38 (2023).","journal-title":"npj Digit Med"},{"key":"174_CR10","unstructured":"U.S. Food & Drug Administration. Device Software Functions Including Mobile Medical Applications. https:\/\/www.fda.gov\/medical-devices\/digital-health-center-excellence\/device-software-functions-including-mobile-medical-applications#a, September 2022."},{"key":"174_CR11","unstructured":"U.S. Food & Drug Administration. CFR - Code of Federal Regulations Title 21. 08.24. https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfcfr\/cfrsearch.cfm?fr=882.5801"},{"key":"174_CR12","unstructured":"U.S. Food & Drug Administration. Class II Special Controls Documents. https:\/\/www.fda.gov\/medical-devices\/guidance-documents-medical-devices-and-radiation-emitting-products\/class-ii-special-controls-documents, June 2022."},{"key":"174_CR13","unstructured":"U.S. Food & Drug Administration. De Novo Classification Request. https:\/\/www.fda.gov\/medical-devices\/premarket-submissions-selecting-and-preparing-correct-submission\/de-novo-classification-request, April 2022."},{"key":"174_CR14","unstructured":"U.S. Food & Drug Administration. 510 Premarket Notification. https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfcfr\/cfrsearch.cfm?fr=882.5801, March 30, 2024."},{"key":"174_CR15","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/s41746-024-01021-y","volume":"7","author":"M Aboy","year":"2024","unstructured":"Aboy, M., Crespo, C. & Stern, A. Beyond the 510(k): The regulation of novel moderate-risk medical devices, intellectual property considerations, and innovation incentives in the FDA\u2019s De Novo pathway. npj Digit Med. 7, 29 (2024).","journal-title":"npj Digit Med"},{"key":"174_CR16","doi-asserted-by":"publisher","first-page":"1086219","DOI":"10.3389\/fdgth.2023.1086219","volume":"5","author":"A Watson","year":"2023","unstructured":"Watson, A., Chapman, R., Shafai, G. & Maricich, Y. A. FDA regulations and prescription digital therapeutics: Evolving with the technologies they regulate. Front Digit Health 5, 1086219 (2023).","journal-title":"Front Digit Health"},{"key":"174_CR17","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.7326\/ANNALS-24-00728","volume":"177","author":"KT Kadakia","year":"2024","unstructured":"Kadakia, K. T., Rathi, V. K., Dhruva, S. S., Ross, J. S. & Krumholz, H. M. Modernizing Medical Device Regulation: Challenges and Opportunities for the 510(k) Clearance Process. Ann. Intern Med. 177, 1558\u20131565 (2024).","journal-title":"Ann. Intern Med"},{"key":"174_CR18","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1001\/jamainternmed.2020.3214","volume":"180","author":"JL Johnston","year":"2020","unstructured":"Johnston, J. L., Dhruva, S. S., Ross, J. S. & Rathi, V. K. Clinical Evidence Supporting US Food and Drug Administration Clearance of Novel Therapeutic Devices via the De Novo Pathway Between 2011 and 2019. JAMA Intern Med. 180, 1701 (2020).","journal-title":"JAMA Intern Med"},{"key":"174_CR19","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1056\/NEJMp1908654","volume":"381","author":"VK Rathi","year":"2019","unstructured":"Rathi, V. K. & Ross, J. S. Modernizing the FDA\u2019s 510(k) Pathway. N. Engl. J. Med. 381, 1891\u20131893 (2019).","journal-title":"N. Engl. J. Med"},{"key":"174_CR20","unstructured":"U.S. Food & Drug Administration. Device Classification Under Section 513(f)(2)(De Novo). https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfpmn\/denovo.cfm?start_search=41&center=&panel=NE&productcode=&knumber=&denknumber=&applicant=&devicename=&type=&thirdpartyreviewed=&expeditedreview=&decision=&decisiondatefrom=&decisiondateto=01%2F13%2F2025&denovo=&ivdproducts=&pagenum=10&sortcolumn=decisiondatedesc, January 2025."},{"key":"174_CR21","unstructured":"U.S. Food & Drug Administration. DE NOVO CLASSIFICATION REQUEST FOR RESET. https:\/\/www.accessdata.fda.gov\/cdrh_docs\/reviews\/DEN160018.pdf, May 2016."},{"key":"174_CR22","unstructured":"U.S. Food & Drug Administration. De novo classification request for EndeavorRx. https:\/\/www.accessdata.fda.gov\/cdrh_docs\/reviews\/DEN200026.pdf, April 2020."},{"key":"174_CR23","unstructured":"U.S. Food & Drug Administration. De novo classification request for EASEVRx. https:\/\/www.accessdata.fda.gov\/cdrh_docs\/reviews\/DEN210014.pdf, March 2021."},{"key":"174_CR24","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1080\/03007995.2020.1846022","volume":"37","author":"YA Maricich","year":"2021","unstructured":"Maricich, Y. A. et al. Safety and efficacy of a prescription digital therapeutic as an adjunct to buprenorphine for treatment of opioid use disorder. Curr. Med. Res. Opin. 37, 167\u2013173 (2021).","journal-title":"Curr. Med. Res. Opin."},{"key":"174_CR25","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/S2215-0366(15)00536-2","volume":"3","author":"H Christensen","year":"2016","unstructured":"Christensen, H. et al. Effectiveness of an online insomnia program (SHUTi) for prevention of depressive episodes (the GoodNight Study): a randomised controlled trial. Lancet Psychiatry 3, 333\u2013341 (2016).","journal-title":"Lancet Psychiatry"},{"key":"174_CR26","unstructured":"U.S. Food & Drug Administration. Rejoyn FDA authorization. https:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf23\/K231209.pdf, March 30, 2024."},{"key":"174_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2025.119409","volume":"388","author":"B Rothman","year":"2025","unstructured":"Rothman, B. et al. A digital therapeutic (CT-152) as adjunct to antidepressant medication: A phase 3 randomized controlled trial (the Mirai study). J. Affect. Disord. 388, 119409 (2025).","journal-title":"J. Affect. Disord."},{"key":"174_CR28","unstructured":"U.S. Food & Drug Administration. Sleepio FDA authorization. https:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf23\/K233577.pdf, August 5, 2024."},{"key":"174_CR29","unstructured":"U.S. Food & Drug Administration. Daylight FDA authorization. https:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf23\/K233872.pdf, August 30, 2024."},{"key":"174_CR30","unstructured":"U.S. Food & Drug Administration. MamaLift Plus FDA authorization. https:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf22\/K223515.pdf, April 22, 2024."},{"key":"174_CR31","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s40501-023-00290-w","volume":"10","author":"C Blease","year":"2023","unstructured":"Blease, C. Out of control: how to design digital placebos. Curr. Treat. Options Psych. 10, 109\u2013118 (2023).","journal-title":"Curr. Treat. Options Psych."},{"key":"174_CR32","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.invent.2018.03.006","volume":"12","author":"LG Morrison","year":"2018","unstructured":"Morrison, L. G. et al. Comparing usage of a web and app stress management intervention: An observational study. Internet Interventions 12, 74\u201382 (2018).","journal-title":"Internet Interventions"},{"key":"174_CR33","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1525\/jer.2010.5.3.57","volume":"5","author":"E Ripley","year":"2010","unstructured":"Ripley, E., Macrina, F., Markowitz, M. & Gennings, C. Who\u2019s Doing the Math? Are We Really Compensating Research Participants? J. Empir. Res. Hum. Res. Ethics 5, 57\u201365 (2010).","journal-title":"J. Empir. Res. Hum. Res. Ethics"},{"key":"174_CR34","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.cct.2015.08.014","volume":"45","author":"DM Swanson","year":"2015","unstructured":"Swanson, D. M. & Betensky, R. A. Research participant compensation: A matter of statistical inference as well as ethics. Contemp. Clin. Trials 45, 265\u2013269 (2015).","journal-title":"Contemp. Clin. Trials"},{"key":"174_CR35","unstructured":"The Institute for Clinical and Economic Review (ICER). ICER Publishes Evidence Report on Digital Therapeutics for Opioid Use Disorder. https:\/\/icer.org\/news-insights\/press-releases\/icer-publishes-evidence-report-on-digital-therapeutics-for-opioid-use-disorder\/, November 2020."},{"key":"174_CR36","unstructured":"Institute of Data. Evidence Rating Matrix. https:\/\/icer.org\/evidence-rating-matrix\/, 2023."},{"key":"174_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajp.2024.104147","volume":"99","author":"P Pokhrel","year":"2024","unstructured":"Pokhrel, P., Rath, S., Aggarwal, R., Shah, S. T. & Ahmadi, L. Enhancing mental wellness: A reflection on Rejoyn app\u2019s FDA approval for depression management. Asian J. Psychiatry 99, 104147 (2024).","journal-title":"Asian J. Psychiatry"},{"key":"174_CR38","doi-asserted-by":"publisher","unstructured":"Richmond L. M. Rejoyn: First App Cleared by FDA for Depression; Cost, Efficacy Unclear. PN. 59:appi.pn.2024.06.6.15. https:\/\/doi.org\/10.1176\/appi.pn.2024.06.6.15. 2024.","DOI":"10.1176\/appi.pn.2024.06.6.15"},{"key":"174_CR39","doi-asserted-by":"publisher","unstructured":"Zagorski N. Jury Still Out on Digital Therapies for ADHD. January, https:\/\/doi.org\/10.1176\/appi.pn.2024.02.1.5. 2024.","DOI":"10.1176\/appi.pn.2024.02.1.5"},{"key":"174_CR40","unstructured":"UnitedHealthcare. Prior Authorization\/Medical Necessity \u2013 Digital Applications. https:\/\/www.uhcprovider.com\/content\/dam\/provider\/docs\/public\/prior-auth\/drugs-pharmacy\/commercial\/a-g\/PA-Med-Nec-Digital-Applications.pdf, January 2024."},{"key":"174_CR41","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1001\/jamainternmed.2015.7155","volume":"176","author":"VL Jacoby","year":"2016","unstructured":"Jacoby, V. L., Subak, L. & Waetjen, L. E. The FDA and the Vaginal Mesh Controversy\u2014Further Impetus to Change the 510(k) Pathway for Medical Device Approval. JAMA Intern. Med. 176, 277 (2016).","journal-title":"JAMA Intern. Med."},{"key":"174_CR42","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1056\/NEJMp1211581","volume":"368","author":"BM Ardaugh","year":"2013","unstructured":"Ardaugh, B. M., Graves, S. E. & Redberg, R. F. The 510(k) Ancestry of a Metal-on-Metal Hip Implant. N. Engl. J. Med. 368, 97\u2013100 (2013).","journal-title":"N. Engl. J. Med"},{"key":"174_CR43","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s44247-024-00092-x","volume":"2","author":"C Prentice","year":"2024","unstructured":"Prentice, C. et al. Methods for evaluating the efficacy and effectiveness of direct-to-consumer mobile health apps: a scoping review. BMC Digit Health 2, 31 (2024).","journal-title":"BMC Digit Health"},{"key":"174_CR44","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/s41746-022-00668-9","volume":"5","author":"J Torous","year":"2022","unstructured":"Torous, J., Stern, A. D. & Bourgeois, F. T. Regulatory considerations to keep pace with innovation in digital health products. npj Digit Med 5, 121 (2022).","journal-title":"npj Digit Med"},{"key":"174_CR45","unstructured":"U.S. Food & Drug Administration. Digital Health Software Precertification (Pre-Cert) Pilot Program. https:\/\/www.fda.gov\/medical-devices\/digital-health-center-excellence\/digital-health-software-precertification-pre-cert-pilot-program, September 2022."},{"key":"174_CR46","unstructured":"Ferdous A. F. FDA acknowledges shortcomings of Pre-Cert pilot in report. Regulatory Focus. October https:\/\/www.raps.org\/news-and-articles\/news-articles\/2022\/10\/fda-acknowledges-shortcomings-of-pre-cert-pilot-in, 2022."},{"key":"174_CR47","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/s41746-024-01137-1","volume":"7","author":"L Schmidt","year":"2024","unstructured":"Schmidt, L., Pawlitzki, M., Renard, B. Y., Meuth, S. G. & Masanneck, L. The three-year evolution of Germany\u2019s Digital Therapeutics reimbursement program and its path forward. npj Digit Med. 7, 139 (2024).","journal-title":"npj Digit Med."},{"key":"174_CR48","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41746-020-0306-7","volume":"3","author":"S Gerke","year":"2020","unstructured":"Gerke, S., Stern, A. D. & Minssen, T. Germany\u2019s digital health reforms in the COVID-19 era: lessons and opportunities for other countries. npj Digit Med. 3, 94 (2020).","journal-title":"npj Digit Med"},{"key":"174_CR49","unstructured":"U. S. Food & Drug Administration. Deciding When to Submit a 510(k) for a Change to an Existing Device. https:\/\/www.fda.gov\/media\/99812\/download?attachment, October 25, 2017."},{"key":"174_CR50","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.drugalcdep.2016.01.021","volume":"161","author":"SM Murphy","year":"2016","unstructured":"Murphy, S. M. et al. Cost-effectiveness of an internet-delivered treatment for substance abuse: Data from a multisite randomized controlled trial. Drug Alcohol Depend. 161, 119\u2013126 (2016).","journal-title":"Drug Alcohol Depend."},{"key":"174_CR51","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1001\/jamapsychiatry.2016.3249","volume":"74","author":"LM Ritterband","year":"2017","unstructured":"Ritterband, L. M. et al. Effect of a Web-Based Cognitive Behavior Therapy for Insomnia Intervention With 1-Year Follow-up: A Randomized Clinical Trial. JAMA Psychiatry 74, 68 (2017).","journal-title":"JAMA Psychiatry"},{"key":"174_CR52","doi-asserted-by":"publisher","first-page":"e168","DOI":"10.1016\/S2589-7500(20)30017-0","volume":"2","author":"SH Kollins","year":"2020","unstructured":"Kollins, S. H. et al. A novel digital intervention for actively reducing severity of paediatric ADHD (STARS-ADHD): a randomised controlled trial. Lancet Digital Health 2, e168\u2013e178 (2020).","journal-title":"Lancet Digital Health"},{"key":"174_CR53","unstructured":"U.S. Food & Drug Administration. EndeavorRx v3.0 FDA authorization. https:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf23\/K231337.pdf, December 13, 2023."},{"key":"174_CR54","unstructured":"U.S. Food & Drug Administration. EndeavorOTC FDA authorization. http:\/\/accessdata.fda.gov\/cdrh_docs\/pdf23\/K233496.pdf, June 14, 2024."},{"key":"174_CR55","doi-asserted-by":"publisher","first-page":"e37480","DOI":"10.2196\/37480","volume":"24","author":"L Garcia","year":"2022","unstructured":"Garcia, L. et al. Durability of the Treatment Effects of an 8-Week Self-administered Home-Based Virtual Reality Program for Chronic Low Back Pain: 6-Month Follow-up Study of a Randomized Clinical Trial. J. Med Internet Res. 24, e37480 (2022).","journal-title":"J. Med Internet Res"},{"key":"174_CR56","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1097\/j.pain.0000000000003198","volume":"165","author":"M \u010ceko","year":"2024","unstructured":"\u010ceko, M., Baeuerle, T., Webster, L., Wager, T. D. & Lumley, M. A. The effects of virtual reality neuroscience-based therapy on clinical and neuroimaging outcomes in patients with chronic back pain: a randomized clinical trial. Pain 165, 1860\u20131874 (2024).","journal-title":"Pain"},{"key":"174_CR57","unstructured":"U.S. Food & Drug Administration. RelieVRx FDA authorization. https:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf24\/K243417.pdf,"},{"key":"174_CR58","unstructured":"U.S. Food & Drug Administration. 510(k) Summary For The Intercure Ltd. RESPeRATE. Published online https:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf2\/k020399.pdf?utm_source=chatgpt.com, January 2002."},{"key":"174_CR59","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.jpsychires.2007.06.005","volume":"42","author":"AE Meuret","year":"2008","unstructured":"Meuret, A. E., Wilhelm, F. H., Ritz, T. & Roth, W. T. Feedback of end-tidal pCO2 as a therapeutic approach for panic disorder. J. Psychiatr. Res. 42, 560\u2013568 (2008).","journal-title":"J. Psychiatr. Res."},{"key":"174_CR60","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1037\/a0019552","volume":"78","author":"AE Meuret","year":"2010","unstructured":"Meuret, A. E., Rosenfield, D., Seidel, A., Bhaskara, L. & Hofmann, S. G. Respiratory and cognitive mediators of treatment change in panic disorder: Evidence for intervention specificity. J. Consulting Clin. Psychol. 78, 691\u2013704 (2010).","journal-title":"J. Consulting Clin. Psychol."},{"key":"174_CR61","unstructured":"ClinicalTrials.gov. Investigation of the Freespira Breathing System in the Treatment of Post Traumatic Stress Disorder (PTSD). NCT03039231. Published online March 25, 2020."}],"container-title":["npj Mental Health Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s44184-025-00174-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44184-025-00174-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44184-025-00174-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T11:20:12Z","timestamp":1764156012000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s44184-025-00174-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,26]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["174"],"URL":"https:\/\/doi.org\/10.1038\/s44184-025-00174-2","relation":{},"ISSN":["2731-4251"],"issn-type":[{"value":"2731-4251","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,26]]},"assertion":[{"value":"24 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"62"}}